The protective effects of omega - 3 fatty acids against MK-801-induced neurotoxicity in prefrontal cortex of rat

Neurochemistry International

Volumn 50, Issue 1, 2007, Pages 196-202

  Ozyurt, Birsen ^a   Sarsilmaz, Mustafa ^b   Akpolat, Nusret ^b   Ozyurt, Huseyin ^a   Akyol, Omer ^c   Herken, Hasan ^d   Kus, Ilter ^b  

^a GAZIOSMANPASA UNIVERSITY   (Turkey)

^b FIRAT UNIVERSITY   (Turkey)

^c HACETTEPE UNIVERSITY   (Turkey)

^d PAMUKKALE UNIVERSITY   (Turkey)

Author keywords

Apoptosis; Malondialdehyde; MK 801; Omega 3 fatty acids; Oxidative stress; Prefrontal cortex; Protein carbonyl

Indexed keywords

ADENOSINE DEAMINASE; CARBONYL DERIVATIVE; CATALASE; DIZOCILPINE; DOCOSAHEXAENOIC ACID; GLUTATHIONE PEROXIDASE; ICOSAPENTAENOIC ACID; MALONALDEHYDE; MARINCAP; NITRIC OXIDE; OMEGA 3 FATTY ACID; SUPEROXIDE DISMUTASE; XANTHINE OXIDASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DECAPITATION; DIET SUPPLEMENTATION; DRUG MECHANISM; ENZYME ACTIVITY; EXPERIMENTAL ANIMAL; HISTOLOGY; LIPID PEROXIDATION; MALE; MICROSCOPY; NEUROCHEMISTRY; NEUROPATHOLOGY; NEUROPHYSIOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATION KINETICS; OXIDATIVE STRESS; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROGNOSIS; PSYCHOSIS; RAT; RAT STRAIN; SCHIZOPHRENIA; STATISTICAL SIGNIFICANCE;

ANIMALS; DIZOCILPINE MALEATE; MALE; RATS;

EID: 33845285848     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2006.08.002     Document Type: Article

References (59)

1. Aebi H. Catalase. In: Bergmeyer H.U. (Ed). Methods of Enzymatic Analysis (1974), Academic Press, New York
2. Akil M., and Lewis D.A. Reduced dopamine innervation of the prefrontal cortex in schizophrenia. Soc. Neurosci. Abstr. 22 (1996) 1679
3. Akyol O. Increased lipid peroxidation in schizophrenia: a marker of membrane breakdown. Eur. Psyhiatr. 17 Suppl. 75S (2002)
4. Akyol O., Herken H., Uz E., Fadillioglu E., Unal S., Sogut S., Ozyurt H., and Savas H.A. The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients: the possible role of oxidant/antioxidant imbalance. Prog. Neuropsychopharmacol. Biol. Psychiatr. 26 (2002) 995-1005
5. Albrecht J., and Wegrzynowicz M. Endogenous neuroprotectants in ammonia toxicity in the central nervous system: facts and hypotheses. Metab. Brain Dis. 20 4 (2005) 253-263
6. Andine P., Widermark N., Axelsson R., Nyberg G., Olofsson U., Martensson E., and Sandberg M. Characterization of MK-801-induced behavior as a putative rat model of psychosis. J. Pharmacol. Exp. Ther. 290 (1999) 1393-1408
7. Broadbelt K., Byne W., and Jones L.B. Evidence for a decrease in basilar dendrites of pyramidal cells in schizophrenic medial prefrontal cortex. Schizophr. Res. 58 (2002) 75-81
8. Bubenikova-Valesova V., Balcar V.J., Tejkalova H., Langmeier M., and St'astny F. Neonatal administration of N-acetyl-l-glutamate induces early neurodegeneration in hippocampus and alters behaviour in young adult rats. Neurochem. Int. 48 6-7 (2006) 515-522
9. Clinton D.K. The changing roles and targets for animal models of schizophrenia. Biol. Psychiatr. 50 (2001) 845-855
10. Corso T.D., Sesma M.A., Tenkova T.I., Der T.C., Wozniak D.F., Farber N.B., and Olney J.W. Multifocal brain damage induced by phencyclidine is augmented by pilocarpine. Brain Res. 752 (1997) 1-14
11. Cortas N.K., and Wakid N.W. Determination of inorganic nitrate in serum and urine by a kinetic cadmium-reduction method. Clin. Chem. 36 (1990) 1440-1443
12. Davis K.L., Kahn R.S., Ko G., and Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatr. 148 (1991) 1474-1486
13. Daviss S.R., and Lewis D.A. Local circuit neurons of the prefrontal cortex in schizophrenia: selective increase in the density of calbindin-immunoreactive neurons. Psychiatr. Res. 59 (1995) 81-96
14. Deutsch S.I., Rosse R.B., Billigslea E.N., Bellack A.S., and Mastropaolo J. Topiramate antagonizes MK-801 in an animal model of schizophrenia. Eur. J. Pharmacol. 449 (2002) 121-125
15. du Bois T.M., Deng C., and Huang X.F. Membrane phospholipid composition, alterations in neurotransmitter systems and schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry. 29 (2005) 878-888
16. Esterbaur H., and Cheeseman K.H. Determination of aldehydic lipid peroxidation products:malonaldehyde and 4-hyroxynonenal. In: Packer L., and Glazer A.N. (Eds). Methods in Enzimology, Oxygen Radicals in Biological systems vol. 186 (1990), Academic Press, New York 407-421
17. Eyjolfsson E.M., Brenner E., Kondziella D., and Sonnewald U. Repeated injection of MK801: an animal of schizophrenia?. Neurochem. Int. 48 (2006) 541-546
18. Fenton W.S., Hibbeln J., and Knable M. Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. Biol. Psychiatr. 47 (2000) 8-21
19. Giusti G. Adenosine deaminase. In: Bergmeyer M.V. (Ed). Methods of Enzymatic Analysis. 2nd ed. (1974), Academic Press, New York 1092-1098
20. Haag M. Essential fatty acids and the brain. Can. J. Psychiatr. 48 (2003) 195-203
21. Halliwell B. Reactive oxygen species and the central nervous system. J. Neurochem. 59 (1992) 1609-1623
22. Haris, L.W., Sharp, T., Harrison, P.J., 2003. A neurodevelopmental, glutamergic model relevant to schizophrenia? MK-801-induced apoptosis in the neonatal rat produces molecular changes in the adult brain. Abstract. International Congress on Schizophrenia Research, Neuroanatom., Anim. 4, 57.
23. Herken H., Uz E., Ozyurt H., Sogut S., Virit O., and Akyol O. Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia. Mol. Psychiatr. 6 (2001) 66-73
24. Horrobin D.F. The membrane phospholipid hypothesis of schizophrenia. Schizophr. Res. 13 (1994) 195-207
25. Horrobin D.F., Manku M.S., Hillman S., and Glen I.A.M. Fatty acid levels in brains of schizophrenic and normal controls. Biol. Psychiatr. 30 (1991) 795-805
26. Irmak M.K., Koltuksuz U., Kutlu N.O., Yaǧmurca M., Ozyurt H., Karaman A., and Akyol O. The effect of Caffeic acid phenethyl ester on ischemia-reperfusion injury in comparison with alpha-tocopherol in rat kidneys. Urol. Res. 29 (2001) 190-193
27. Ikonomidou C., Bosch F., Miksa M., Bittigau P., Vockler J., Dikranian K., Stefovska V., Turski L., and Olney J.W. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science 283 (1999) 70-74
28. Javitt D.C., and Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatr. 148 (1991) 1301-1308
29. Levine R.L., Garland D., Oliver C.N., Amici A., Climent I., Lenz A.G., Ahn B.W., Shaltiel S., and Stantman E.R. Determination of carbonyl content in oxidatively modified proteins. In: Packer L., and Glazer A.N. (Eds). Methods in Enzimology, Oxygen Radicals in Biological Systems vol. 186 (1990), Academic Press, New York 464-478
30. Lohr J.B. Oxygen radicals and neuropsychiatric illness: some speculations. Arch. Gen. Psychiatr. 48 (1991) 1097-1106
31. Lowry O., Rosenbraugh N., Farr L., and Rondal R. Protein measurements with the folin-phenol reagent. J. Biol. Chem. 183 (1951) 265-275
32. Mahadik S.P., Evans D., and Lal H. Oxidative stres and role of antioxidant and ω - 3 essential fatty acid supplemention in schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatr. 25 (2001) 463-493
33. Mahadik S.P., and Mukherjee S. Free radical pathology and antioxidant defense in schizophrenia: a review. Schizophr. Res. 19 (1996) 1-17
34. Mastropaolo J., Rosse R.B., and Deutsch S.I. Anabasine, a selective nicotinic acetylcholine receptor agonist, antagonizes MK-801-elicited mouse popping behavior, an animal model of schizophrenia. Behav. Brain Res. 153 (2004) 419-422
35. Miller E.K. The prefrontal cortex: complex neural properties for complex behavior. Neuron 22 (1999) 15-17
36. O'Donnell P., and Grace A.A. Dysfunction in multiple interrelated systems as the neurobiological bases of schizophrenic symptom clusters. Schizophr. Bull. 24 (1998) 267-283
37. Olney J.W., and Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatr. 52 (1995) 998-1007
38. Olney J.W., Labruyere J., and Price M.T. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 244 (1989) 1360-1362
39. Olney J.W., Newcomer J.W., and Farber N.B. NMDA receptor hypofunction model of schizophrenia. J. Psychiatr. Res. 33 (1999) 523-533
40. Paglia D.E., and Valentine W.N. Studies on the quantitive and qualitative characterization of erythrocyte glutathione peroxidase. J. Lab. Clin. Med. 70 (1967) 158-170
41. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates vol. 2 (1986), Academic Press, New York
42. Peet M. New strategies for the treatment of schizophrenia: ω - 3 polyunsaturated fatty acids. In: Peet M., Gleen I., and Horrobin D.F. (Eds). Phospholipid Spectrum Disorder in Psychiatry (1999), Marius Press, Lancashire, UK 189-192
43. Pohl D., Bittigau P., Ishimaru M., Stadhaus D., Hubner C., Olney J.W., Turski L., and Ikonomidou C. N-Methyl-d-aspartate antagonists and apoptotic cell death triggered by head trauma in developing rat brain. PNAS 96 (1999) 2508-2513
44. Prajda N., and Weber G. Malign transformation-linked imbalance: decreased XO activity in hepotomas. FEBS Lett. 59 (1975) 245-249
45. Puri B.K., and Richarson A.J. Sustained remission of positive and negative symptoms of schizophrenia after treatment with eicosapentaenoic acid (letter). Arch. Gen. Psychiatr. 55 (1998) 188-189
46. Rung J.P., Carlsson A., Markinhuhta K.R., and Carlsson M.L. (+)-MK-801 induced social withdrawal in rats; a model for negative symptoms of schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatr. 29 (2005) 827-832
47. Rajkowska G., Miguel-Hidalgo J.J., Makkos Z., Meltzer H., Overholser J., and Stockmeier C. Layer-specific reductions in GFAP-reactive astroglia in the dorsolateral prefrontal cortex in schizophrenia. Schizophr. Res. 57 (2002) 127-138
48. Reddy R.D., and Yao J.K. Free radical pathology in schizophrenia: a review. Prostagland. Leukot. Essent. Fatty Acids 55 (1996) 33-43
49. Roth K.A., and D'Sa C. Apoptosis and brain development. MRDD Res. Rev. 7 (2001) 261-266
50. Sun Y., Oberley L.W., and Ying L. A simple method for clinical assay of superoxide dismutase. Clin. Chem. 34 (1988) 497-500
51. Tamminga C.A., Holcomb H.H., Gao X.M., and Lahti A.C. Glutamate pharmacology and the treatment of schizophrenia: current status and future directions. Int. Clin. Psychopharmacol. 10 Suppl. 3 (1995) S29-S37
52. Tanji J., and Hoshi E. Behavioral planning in the prefrontal cortex. Curr. Opin. Neurobiol. 11 (2001) 164-170
53. Tiedtke P.I., Bischoff C., and Schmidt W.J. MK-801-induced stereotypy and its antagonism by neuroleptic drugs. J. Neural. Transm. Gen. Sect. 81 (1990) 173-182
54. Wang C., Kaufmann J.A., Sanchez-Ross M.G., and Johnson K.M. Mechanisms of N-methyl-d-aspartate-induced apoptosis in phencyclidine-treated cultured forebrain neurons. J. Pharmacol. Exp. Ther. 294 (2000) 287-295
55. Weinberger D.R., Berman K.F., and Illowsky B. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. III. A new cohort and evidence for a monoaminergic mechanisms. Arch. Gen. Psychiatr. 45 (1988) 609-615
56. Wozniak D.F., Dikranian K., Ishimaru M., Nardi A., Corso T.D., Tenkova T.I., Olney J.W., and Fix A.S. Disseminated corticolimbic neuronal degenaration induced in rat brain by MK-801: potential relevance to Alzheimer's disease. Neurobiol. Dis. 5 (1998) 305-322
57. Yao J.K., Leonard S., and Reddy R.D. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophr. Res. 42 (2000) 7-17
58. Yehuda S., Rabinovitz S., and Mostofsky D.I. Essential fatty acids are mediators of brain biochemistry and cognitive functions. J. Neurosci. Res. 56 (1999) 565-570
59. Zhang X., Boulton A.A., Zuo D.M., and Yu P.H. MK-801 induces apoptotic neuronal death in the rat retrosplenial cortex: Prevention by cycloheximide and R(-)-2-hexyl-N-methylpropargylamine. J. Neurosci. Res. 46 (1996) 82-89